コエンザイムQ10の補給は,新しい毎日の持続的な頭痛の解消と相関する可能性があります
Mrinmayee Takle1, Jeffrey Strelzik1, Raquel Langdon1
1Division of Neurology, The George Washington University/Children's National Hospital, Washington, DC, USA.
Journal of child neurology
|September 1, 2025
まとめ
小児の新発の日常的な頭痛は,コエンザイムQ10 (CoQ10) 補給により改善される可能性があります. 定期的な運動やマグネシウムなどの治療法も この慢性的な頭痛症候群の 解決に有益であることが示されました
科学分野:
- 神経学
- 小児頭痛障害
背景:
- 新型日常頭痛 (NDPH) は,慢性で治療に抵抗する一次性頭痛障害である.
- 生活の質に影響を与える NDPHの効果的な管理に関するガイドラインは限られている.
- NDPHの症状解消のための標的治療法を特定した研究はほとんどありません.
研究 の 目的:
- NDPHと診断された小児患者のアウトカムを記述する.
- 小児のNDPHにおける特定の介入と頭痛解消の関連性を評価する.
- NDPHの潜在的治療標的を特定する.
主な方法:
- 子どもの国立病院の患者登録を振り返る
- NDPHと診断された小児患者を含む.
- 人口統計的特徴,臨床的特徴,以前の治療法,および解消率の分析
- 治癒した頭痛と治癒しなかった頭痛の統計的比較
主要な成果:
- 182人の小児患者 (平均年齢15. 5歳; 78%が女性) が含まれていた.
- 47人の患者 (25. 8%) で頭痛が解消した.
- コエンザイムQ10 (CoQ10) 補給は頭痛の解消と有意に関連していました (17%対4%,P=0. 010).
- マグネシウム,トピラマート,オナボトキシンAの注射は 有意な傾向を示した.
- 定期的な運動は,より高い解消率 (P=0.058) と関連付けられました.
結論:
- コエンザイムQ10 (CoQ10) 補給は,小児のNDPH解消に役割を果たす可能性があります.
- 運動,マグネシウム,トピラマート,オナボトゥリヌム毒素Aの注射は,潜在的な利点を提供することができます.
- 原因関係を確立し,NDPHの治療戦略を最適化するために,さらなる前向きな研究とランダム化制御試験が必要である.
関連する概念動画
Hypertension III: Clinical Manifestations and Diagnostic Studies
48
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
48
Rheumatic Heart Disease III: Medical Management
31
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
31
Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.6K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.6K
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33


